drugset / Trial / NCT06227377
QTX3034 in Patients With KRAS G12D Mutation
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Timeline
- Start
- 2024-02-05
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | QTX3034 | Unknown | — | — |